newsfilter
← Earnings
Earnings Releases·

Dyadic International, Inc. — Third Quarter 2026 Earnings Summary

  • Total revenue declined 61.4% year-over-year to $449,101, driven by a $538,199 drop in grant revenue and a $187,728 decrease in R&D revenue, while net loss narrowed to $1.36 million from $1.98 million in the prior-year period.
  • Stockholders' equity turned negative to $(2.58) million as of September 30, 2026, and management has concluded there is substantial doubt regarding the company's ability to continue as a going concern for the next 12 months.
  • The company recorded its first direct commercial sales of recombinant transferrin and DNase I, with a $225,000 milestone payment from a second chymosin product expected in Q4 2026.
  • Dyadic is evaluating financing alternatives and prioritizing larger strategic partnerships, licensing arrangements, and potential transactions to strengthen its balance sheet and accelerate commercialization.
Company
DYADIC INTERNATIONAL INC
Sector
Healthcare
Industry
Biotechnology